Brunetti Barbara, de Biase Dario, Dellapina Giulia, Muscatello Luisa Vera, Ingravalle Francesco, Tura Giorgia, Bacci Barbara
Department of Veterinary Medical Sciences, University of Bologna, 40126 Bologna, Italy.
Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Animals (Basel). 2023 Mar 1;13(5):899. doi: 10.3390/ani13050899.
In human medicine, p53 immunohistochemistry (IHC) is a common method that is used for the identification of tumors with mutations. In veterinary medicine, several studies have performed IHC for p53 in canine tumors, but it is not known how well it actually predicts the mutation. The aim of this study was to estimate the accuracy of the IHC method for p53 (clone PAb240) using a lab-developed NGS panel to analyze mutations in a subset of malignant tumors in dogs. A total of 176 tumors were analyzed with IHC and then 41 were subjected to NGS analysis; among them, 15 were IHC positive and 26 were negative, and 16 out of 41 (39%) were found to be inadequate for NGS analysis. Excluding the non-evaluable cases at NGS, of the remaining eight IHC-positive cases, six were mutants and two were wild-type. Among the 17 IHC-negative cases, 13 were wild type, and 4 were mutants. The sensitivity was 60%, specificity was 86.7%, and the accuracy was 76%. These results suggest that when using IHC for p53 with this specific antibody to predict mutation, up to 25% wrong predictions can be expected.
在人类医学中，p53免疫组化（IHC）是用于识别有突变肿瘤的常用方法。在兽医学中，已有多项研究对犬类肿瘤进行了p53免疫组化检测，但尚不清楚其实际预测突变的效果如何。本研究的目的是使用实验室开发的二代测序（NGS）检测板来分析犬类恶性肿瘤亚组中的突变，从而评估p53（克隆号PAb240）免疫组化方法的准确性。共对176个肿瘤进行了免疫组化分析，然后对其中41个进行了NGS分析；其中，15个免疫组化呈阳性，26个呈阴性，41个中有16个（39%）被发现不适合进行NGS分析。排除NGS不可评估的病例后，在其余8个免疫组化阳性病例中，6个为突变型，2个为野生型。在17个免疫组化阴性病例中，13个为野生型，4个为突变型。敏感性为60%，特异性为86.7%，准确性为76%。这些结果表明，当使用针对p53的这种特异性抗体通过免疫组化来预测突变时，预计错误预测率可达25%。
